Regen BioPharma Inc - FORM 10-K - EX-32.1 - EXHIBIT 32.1 - December 20, 2016

Attached files

file filename
10-K - FORM 10-K - Regen BioPharma Incrgbp093016form10k.htm
EX-10.70 - EXHIBIT 10.70 - Regen BioPharma Incex10_70.htm
EX-10.71 - EXHIBIT 10.71 - Regen BioPharma Incex10_71.htm
EX-10.72 - EXHIBIT 10.72 - Regen BioPharma Incex10_72.htm
EX-10.73 - EXHIBIT 10.73 - Regen BioPharma Incex10_73.htm
EX-10.75 - EXHIBIT 10.75 - Regen BioPharma Incex10_75.htm
EX-10.76 - EXHIBIT 10.76 - Regen BioPharma Incex10_76.htm
EX-10.77 - EXHIBIT 10.77 - Regen BioPharma Incex10_77.htm
EX-10.78 - EXHIBIT 10.78 - Regen BioPharma Incex10_78.htm
EX-10.79 - EXHIBIT 10.79 - Regen BioPharma Incex10_79.htm
EX-10.80 - EXHIBIT 10.80 - Regen BioPharma Incex10_80.htm
EX-10.81 - EXHIBIT 10.81 - Regen BioPharma Incex10_81.htm
EX-10.82 - EXHIBIT 10.82 - Regen BioPharma Incex10_82.htm
EX-10.83 - EXHIBIT 10.83 - Regen BioPharma Incex10_83.htm
EX-10.84 - EXHIBIT 10.84 - Regen BioPharma Incex10_84.htm
EX-10.85 - EXHIBIT 10.85 - Regen BioPharma Incex10_85.htm
EX-10.86 - EXHIBIT 10.86 - Regen BioPharma Incex10_86.htm
EX-32.2 - EXHIBIT 32.2 - Regen BioPharma Incex32_2.htm
EX-31.2 - EXHIBIT 31.2 - Regen BioPharma Incex31_2.htm
EX-31.1 - EXHIBIT 31.1 - Regen BioPharma Incex31_1.htm

EXHIBIT 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Regen Biopharma, Inc. on Form 10-K for the year ended September 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David R. Koos, Chief Executive Officer certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.  

 

 Dated: December 19, 2016   By: /s/ David R. Koos 
      David R. Koos
      Chief Executive Officer
       

 

 

 

Regen BioPharma Inc Reports